Esperion Therapeutics (ESPR) is a $230.36M market cap biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C), also known as "bad cholesterol," and other cardiometabolic risk factors.
The company was founded in April 2008 by former executives of, and investors in, the original Esperion Therapeutics, Inc. The original Esperion was focused on the research and development of therapies to regulate high-density lipoprotein cholesterol, or HDL-C. After successfully completing a Phase 2a clinical trial with its synthetic HDL therapy, the original Esperion was acquired by Pfizer Inc. (PFE) in 2004 for approximately $1.3 billion.
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: